- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Travere Therapeutics Inc(TVTX)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for TVTX
11/18/2026: TVTX (3-star) is currently NOT-A-BUY. Pass it for now.
Travere Therapeutics is a commercial-stage biopharmaceutical company focused on developing and delivering transformative therapies for rare kidney and metabolic diseases. Its primary business strength is the rapid commercial uptake of its flagship drug, FILSPARI, which is driving robust double-digit revenue growth. The core investment story centers on expanding rare disease market penetration and advancing a clinical pipeline addressing high-unmet-need conditions. However, investors must weigh ongoing net operating losses, heavy reliance on a single lead product, and potential valuation volatility. The stock is best suited for growth-oriented investors willing to tolerate biotech execution risks while monitoring ongoing sales trajectory and regulatory catalysts.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | Travere exhibits high double-digit revenue growth rates driven by the commercial adoption of FILSPARI. |
| Momentum investor | Strong fit while signal remains positive | The stock frequently reacts strongly to clinical data readouts, regulatory decisions, and quarterly sales beats. |
| Value investor | Weak fit | Persistent operating losses and lack of a traditional trailing P/E ratio make it unsuitable for conventional value screens. |
| Dividend investor | Weak fit | The company does not pay a dividend, prioritizing all cash flow for clinical development and commercial expansion. |
| Low-risk investor | Weak fit | High clinical development risks, regulatory dependencies, and equity volatility create substantial risk exposure. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech market sentiment and clinical milestone updates drive sharp swings in the share price. |
| Valuation risk | Medium / high | Valuation relies heavily on long-term commercial projections for FILSPARI rather than current net earnings. |
| Competition risk (rare disease and nephrology biotechnology competition) | Medium / high | Alternative treatments entering the rare kidney disease space could pressure future market adoption. |
| Business quality | Medium | The company possesses defensible orphan drug assets but continues to work toward sustained profitability. |
| Dividend income | Low / none | Income-focused investors receive no dividend yield from the common stock. |
| Execution risk | High | Successful commercial scaling and clinical trial readouts are essential to justify the company's valuation. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.91B USD | Price to earnings Ratio - | 1Y Target Price 73.43 |
Price to earnings Ratio - | 1Y Target Price 73.43 | ||
Volume (30-day avg) 2.0M shares | Beta 1.12 | 52 Weeks Range 22.59 - 68.73 | Updated Date 11/18/2026 |
52 Weeks Range 22.59 - 68.73 | Updated Date 11/18/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.67 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 62.0%
- Active BUY / eligible
- 67 / 108
- 30-Day BUY Count Change
- +22
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Biotechnology
- BUY participation
- 43.6%
- Active BUY / eligible
- 17 / 39
- 30-Day BUY Count Change
- +10
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Rolling Over
The price momentum is slowing down and beginning to turn downward.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 315.26% | Avg. Invested days 48 | Today’s Advisory PASS |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercial Pharmaceuticals | Global sales of approved rare disease prescription therapeutics, led by FILSPARI, Thiola, and Chenodal. | The company generates its core revenue by selling specialized, high-cost medications directly serving niche patient populations with limited treatment alternatives. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Valuation
Trailing PE - | Forward PE 24.69 | Enterprise Value 5.05B | Price to Sales(TTM) 7.53 |
Enterprise Value 5.05B | Price to Sales(TTM) 7.53 | ||
Enterprise Value to Revenue 7.55 | Enterprise Value to EBITDA 828.31 | Shares Outstanding 95.99M | Shares Floating 94.95M |
Shares Outstanding 95.99M | Shares Floating 94.95M | ||
Percent Insiders 0.68 | Percent Institutions 118.99 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

